Simple Summary Prostate cancer can develop under hormone treatment and chemotherapy
from a castration-sensitive towards a castration-resistant into a drug resistant-tumor. The …

Prostate cancer is heterogeneous and patients would benefit from methods that stratify those
who are likely to respond to systemic therapy. Here, we employ single-cell assays for …

Prostate cancer (PCa) is the second most common cancer in men. Common treatments
include active surveillance, surgery, or radiation. Androgen deprivation therapy and …

Advanced and metastatic prostate cancer is often incurable, but its dependency on certain
molecular alterations may provide the basis for targeted therapies. A growing body of …

Background Castration-resistant prostate cancer (CRPC) is one of the main causes of male
cancer mortality. There is currently no effective treatment to cure this deadly prostate cancer …

The mutation-driven transformation of clinical anti-androgen drugs into agonists of the
human androgen receptor (AR) represents a major challenge for the treatment of prostate …

Prostate cancer (PCa) is the most common cancer in men, and this has been mainly noticed
in Western and Asian countries. The aggregations of PCa and castration-resistant PCa …

Prostate cancer (PCa) is one of the most prevalent cancers in men worldwide, and hormonal
therapy plays a key role in the treatment of PCa. However, the drug resistance of hormonal …

Simple Summary Prostate cancer is a malignancy that affects a high number of men all over
the world. When indolent, prostate cancer can remain silent for years without needing …

Prostate cancer (PCa) is today the second most common cancer in the world, with almost
400,000 deaths annually. Multiple factors are involved in the etiology of PCa, such as older …